Here are the latest stories being discussed in biopharma today:

1. Teva to Sell API Unit: As part of a strategic “pivot to growth”, Teva plans to sell its active pharmaceutical ingredients unit. Seen as a move away from its status as a major generics producer, the sale will allow Teva to concentrate on its generics and innovative portfolio.

2. FDA Commissioner Discusses Upcoming Change: The FDA is planning “systemic” changes to its advisory committee process, according to comments by the Commissioner Rob Califf. Few details on the proposed amendments were provided, but the initiative is reportedly being led by Namandjé Bumpus, the FDA’s Chief Scientist.

3. Novavax Announces Staff Layoffs: Vaccine manufacturer Novavax is reducing its full-time workforce by 12% as part of ongoing efforts to respond to a “muted” market. The move follows previous layoffs and cost-cutting measures implemented by the company.

4. Q4 Revenue Slides for Thermo Fisher: Thermo Fisher reported a 5% decline in its fourth-quarter revenue, brought down by a “muted” market. Despite the drop, CEO Marc Casper maintains that 2023 was a strong year given the market challenges.

5. Eli Lilly Advances Health Equity Campaign: Launching a new corporate advertising campaign, Eli Lilly is seeking to boost its branding and reaffirm its commitment to health equity. The campaign has a central message of getting better, highlighting the need for better care irrespective of income levels.

6. Pending SCOTUS Ruling Could Lead to Endless Litigation: A number of groups, including industry organizations, lawmakers, and state legislatures, have urged the Supreme Court to preserve FDA regulations on the abortion pill mifepristone. The high-profile case could potentially reform how the FDA oversees mifepristone distribution.